Dear Sir/Ma''am, Please find unaudited financial results for the quarter and nine months ended on 31.12.2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Omkar Pharmachem reported weak Q3 FY26 results with total income of Rs. 10.50 lakhs, down from Rs. 13.71 lakhs in the same quarter last year — a drop of about 23%. Net sales from operations were zero, with income coming only from other operating sources. Profit after tax fell sharply to Rs. 2.95 lakhs (Q3 FY25: Rs. 8.49 lakhs), a decline of around 65%. For the nine-month period, total income slipped to Rs. 37.94 lakhs from Rs. 40.72 lakhs, and PAT dropped to Rs. 10.68 lakhs from Rs. 22.24 lakhs — a fall of roughly 52%. The auditor (Dipal R. Shah & Co.) issued a clean limited review report with no qualifications.
The company continues to show no core product sales, with shrinking top line and sharply falling profitability — a negative signal for shareholders. Operating margins compressed meaningfully, raising concerns about the sustainability of earnings.